The Day In Review: Biotech Adds On Another 16 Points

July 27, 2005 -- Although it was not a huge gain, biotech put together a thoroughly respectable rise in mid-week trading today. The Centient Biotech 200 was 16 points higher at 3733.77, a rise of .43%. Repligen moved up on much higher earnings, Nymox gained on expanded patent protection, Zars won FDA approval for an anesthesia patch, Schering and AstraZeneca will establish an anti-inflammatory collaboration, Wyeth received FDA approval for a new birth-control pill, Biota set damages in its suit against GlaxoSmithKline, the Chinese pharma Sinovac won Chinese approval for a flu vaccine, and UCB said Cimzia produced positive data against Crohn's disease. More details...